Psilocybin and psilocin research index

Select for export

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology.

Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment-resistant depression because of their ability to alter consciousness and afflicted cognitive processes with lasting effects. We aimed to characterise how psychedelics are currently being investigated to treat substance use disorders (SUD...

Details DOI 10.1111/bph.70181 PubMed 40891276 Copy citation Copy BibTeX

British journal of pharmacology 2026-06-30 Wittenkeller L, Gudelsky G, Winhusen TJ, Amato D

New this week PubMed Published psilocybin DepressionAddictionMechanism of Action Clinical Trial MDMA More

Select for export

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.

Based on its in vitro profile and preliminary evidence, 4-bromo-2,5-dimethoxyphenethylamine (2C-B) may have psychoactive properties that are similar to 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin, which are investigated for the treatment of posttraumatic stress disorder and depressive disorders. We compared acute effects of 2C-B (10, 20, and 30 m...

Details DOI 10.1038/s41386-026-02428-9 PubMed 42049943 Copy citation Copy BibTeX

Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 2026-06-30 Arikci D, Borgulya J, Straumann I, Vizeli P, Luethi D, Thomann J

New this week PubMed Published psilocybin DepressionAnxietyPTSD Clinical Trial More

Select for export

Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects

The acute subjective effects of serotonin (5-HT)2A receptor stimulation with psilocybin in humans are mostly positive. However, negative effects such as anxiety, paranoid thinking, or loss of trust towards other people are common effects, depending on the dose administered, the personality traits of the person consuming it (set), or the environment in which ...

Details Copy citation Copy BibTeX

ClinicalTrials.gov 2026-06-24 University Hospital, Basel, Switzerland

New this month ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyAddiction Qualitative Study Healthy More

Select for export

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment.

Psychedelics, derived from the Greek words "psyche" (soul) and "deloun" (revealing), are substances historically and currently considered "soul-revealing". Also termed hallucinogens due to their impact on sensory perception, they are further categorized into hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and mescaline; entactogens or em...

Details DOI 10.12659/msm.948302 PubMed 40781763 Copy citation Copy BibTeX

Unknown journal 2025-08-08 Silczuk A, Madejek RJ, Koweszko T, Mularczyk-Tomczewska P, Adamska E, Gujski M

Europe PMC Published psilocybin DepressionPTSDAddiction Clinical Trial Humans More

Select for export

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

BACKGROUND AND AIMS: Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin-assisted psychotherapy...

Details DOI 10.1111/add.70152 PubMed 40702912 Copy citation Copy BibTeX

Addiction 2025-07-23 Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul A. Rochefort

OpenAlex Published psilocybin DepressionAnxietyAddiction Randomized Controlled Trial Craving More

Select for export

Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects

4-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and the classic psychedelic substance psilocybin (contained in "magic, hallucinogenic mushrooms"). Pharmacologically, MDMA mainly releases serotonin (5-HT) via the s...

Details Copy citation Copy BibTeX

ClinicalTrials.gov 2025-03-04 University Hospital, Basel, Switzerland

ClinicalTrials.gov CLINICAL TRIAL psilocybinpsilocin DepressionPTSDPharmacology Clinical Trial Healthy More

Select for export

Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.

Background and aimsThis is the first systematic review of the extant literature on all major psychedelic-assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic-assisted treatment for AUD, TUD, and SUD; to evaluate its quality; and to...

Details DOI 10.1111/add.16762 PubMed 39887551 Copy citation Copy BibTeX

Unknown journal 2025-01-29 Piper T, Small F, Brown S, Kelleher M, Mitcheson L, Rucker J

Europe PMC Published psilocybin AddictionClinical TrialRandomized Controlled Trial Randomized Controlled Trial More

Select for export

The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis.

Different study designs of psychedelic trials may impact the blinding and expectance, leading to biased treatment effects. This study aimed to examine the association between antidepressant efficacy and study designs in psychedelic trials. Six databases were systematically searched. Eligible trials were required to investigate the efficacy of psychedelics (p...

Details DOI 10.1016/j.jad.2024.10.016 PubMed 39389119 Copy citation Copy BibTeX

Unknown journal 2024-10-08 Li JR, Chiang KT, Kao YC, Yu CL, Yang FC, Liang CS

Europe PMC Published psilocybin DepressionMeta-Analysis Meta-Analysis Humans More

Select for export

What should constitute a control condition in psychedelic drug trials?

Over the past decade there has been a surge in interest in placebo-controlled trials using non-classical 3,4-methylenedioxymethamphetamine (MDMA) and classical psychedelics such as psilocybin, lysergic acid diethylamide (LSD) and N,N-dimethyltryptamine (DMT) to treat neuropsychiatric disorders. However, the success and reliability of these trials depend on t...

Details DOI 10.1038/s44220-024-00321-2 PubMed 39781538 Copy citation Copy BibTeX

Unknown journal 2024-09-29 Colloca L, Fava M.

Europe PMC Published psilocybin General Other More

Select for export

Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.

BackgroundPsychedelic-assisted therapy refers to a group of therapeutic practices involving psychedelics taken under therapeutic supervision from physicians, psychologists, and others. It has been hypothesised that psychedelic-assisted therapy may reduce symptoms of anxiety, depression, and existential distress in patients facing life-threatening diseases (e...

Details DOI 10.1002/14651858.cd015383.pub2 PubMed 39260823 Copy citation Copy BibTeX

Unknown journal 2024-09-11 Schipper S, Nigam K, Schmid Y, Piechotta V, Ljuslin M, Beaussant Y

Europe PMC Published psilocybin DepressionAnxietyEnd-of-Life Distress Randomized Controlled Trial Humans More

Select for export

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.

ObjectiveTo evaluate the comparative effectiveness and acceptability of oral monotherapy using psychedelics and escitalopram in patients with depressive symptoms, considering the potential for overestimated effectiveness due to unsuccessful blinding.DesignSystematic review and Bayesian network meta-analysis.Data sourcesMedline, Cochrane Central Register of C...

Details DOI 10.1136/bmj-2023-078607 PubMed 39168500 Copy citation Copy BibTeX

Unknown journal 2024-08-20 Hsu TW, Tsai CK, Kao YC, Thompson T, Carvalho AF, Yang FC

Europe PMC Published psilocybin DepressionClinical TrialRandomized Controlled Trial Randomized Controlled Trial Humans More

Select for export

The Black Book of Psychotropic Dosing and Monitoring.

Introduction Since the last edition of the Black Book, several innovative agents have been approved or are poised to be approved in the coming year. These include novel antidepressants, the first muscarine agonist for the treatment of schizophrenia, the first psychedelic which may be approved for the treatment of PTSD (Post Traumatic Stress Disorder), and th...

Details DOI 10.64719/pb.4493 PubMed 38993656 Copy citation Copy BibTeX

Unknown journal 2024-06-30 DeBattista C, Schatzberg AF.

Europe PMC Published psilocybin DepressionAnxietyPTSD Clinical Trial Humans More

Select for export

Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview

Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including conditions that have not benefited from prior interventions. The latter half of the twentieth century marked a revolution in the treatment of depression, anxiety, and psy...

Details DOI 10.31234/osf.io/byms6 Copy citation Copy BibTeX

PsyArXiv 2023-12-25 Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD

PsyArXiv PREPRINT (not peer reviewed) psilocybin DepressionAnxietyPTSD Clinical Trial More

Select for export

Psychedelic Therapy: A Primer for Primary Care Clinicians - Part I. Historical Perspective and Overview

Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including conditions that have not benefited from prior interventions. The latter half of the twentieth century marked a revolution in the treatment of depression, anxiety, and psy...

Details Copy citation Copy BibTeX

PsyArXiv 2023-12-25 Authors unavailable

PsyArXiv PREPRINT (not peer reviewed) psilocybin DepressionAnxietyPTSD Clinical Trial Psychiatry More

Select for export

Dosing Psychedelics and MDMA.

Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine, and mescaline, and entactogens/empathogens, especially 3,4-methylenedioxymethamphetamine, have received renewed attention in psychiatric research and may be developed into medications for such indications as anxiety, depression, cluster headache, and posttraumat...

Details DOI 10.1007/7854_2021_270 PubMed 34734392 Copy citation Copy BibTeX

Unknown journal 2021-12-31 Liechti ME, Holze F.

Europe PMC Published psilocybin DepressionAnxietyPTSD Other N-Methyl-3 More

Select for export

Psychedelic medicines for mood disorders: current evidence and clinical considerations.

Purpose of reviewDespite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. Increased research is occurring, with the pursuit of psychedelic-based pharmacotherapies for a range of mood disorders and other conditions.Recent findingsSerotonergic psychedelics have been found to modulate brain...

Details DOI 10.1097/yco.0000000000000759 PubMed 34855694 Copy citation Copy BibTeX

PubMed 2021-12-31 Sarris J, Pinzon Rubiano D, Day K, Galvão-Coelho NL, Perkins D.

Europe PMC Published psilocybin DepressionPTSDNeuroplasticity Clinical Trial Humans More

Select for export

Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.

Emerging evidence from randomized, double-blind, placebo-controlled clinical trials suggests psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and lysergic acid diethylamide (LSD), when administered as an adjunct to psychotherapy, that is, psychedelic-assisted psychotherapy (PAP), may be beneficial for treating substance use...

Details DOI 10.1037/pha0000490 PubMed 34096755 Copy citation Copy BibTeX

Experimental and Clinical Psychopharmacology 2021-06-06 Fogg C, Michaels TI, de la Salle S, Jahn ZW, Williams MT.

Europe PMC Published psilocybin DepressionAnxietyPTSD Clinical Trial Humans More

Select for export

A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy

After a two-decade hiatus in which research on psychedelics was essentially halted, placebo-controlled clinical trials of psychedelic-assisted therapy for mental health conditions have begun to be published. We identified nine randomized, placebo-controlled clinical trials of psychedelic-assisted therapy published since 1994. Studies examined psilocybin, LSD...

Details DOI 10.31234/osf.io/nhbjk Copy citation Copy BibTeX

PsyArXiv 2020-10-27 Luoma JB, Chwyl C, Bathje G, Davis AK, Lancelotta RL.

PsyArXiv PREPRINT (not peer reviewed) psilocybin DepressionAnxietyPTSD Meta-Analysis More

Select for export

A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy

After a two-decade hiatus in which research on psychedelics was essentially halted, placebo-controlled clinical trials of psychedelic-assisted therapy for mental health conditions have begun to be published. We identified nine randomized, placebo-controlled clinical trials of psychedelic-assisted therapy published since 1994. Studies examined psilocybin, LSD...

Details DOI 10.31234/osf.io/sgujx Copy citation Copy BibTeX

PsyArXiv 2020-06-11 Luoma JB.

PsyArXiv PREPRINT (not peer reviewed) psilocybin DepressionAnxietyPTSD Meta-Analysis More

Select for export

Psilocybin and MDMA reduce costly punishment in the Ultimatum Game.

Disruptions in social decision-making are becoming evident in many psychiatric conditions. These are studied using paradigms investigating the psychological mechanisms underlying interpersonal interactions, such as the Ultimatum Game (UG). Rejection behaviour in the UG represents altruistic punishment - the costly punishment of norm violators - but the mecha...

Details DOI 10.1038/s41598-018-26656-2 PubMed 29844496 Copy citation Copy BibTeX

Scientific Reports 2018-05-28 Gabay AS, Carhart-Harris RL, Mazibuko N, Kempton MJ, Morrison PD, Nutt DJ

Europe PMC Published psilocybin PharmacologyMechanism of ActionEmotional Processing Other Humans More